AVAI BIO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AVAI BIO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2023 | $276.3K | Feb 19, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2023 | ($40.5K) | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | ($210.8K) | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | ($16.5K) | Jun 29, 2022 |
| FY2020 | Mar 31, 2020 | $256.3K | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | $0 | Aug 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.14M) | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | ($2.13M) | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | ($348.9K) | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | ($126.5K) | Jul 13, 2023 |
| FY2021 | Mar 31, 2021 | ($302.3K) | Aug 18, 2021 |
| FY2021 | Mar 31, 2020 | ($69.6K) | Aug 18, 2021 |
| FY2020 | Mar 31, 2019 | ($78.2K) | Aug 13, 2020 |
| FY2019 | Mar 31, 2018 | ($739) | Jul 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.14M) | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | ($2.13M) | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | ($348.9K) | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | $126.5K | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | $302.3K | Jun 29, 2022 |
| FY2020 | Mar 31, 2020 | ($69.6K) | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | ($78.2K) | Aug 13, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Mar 31, 2020 | $27.0K | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | $0 | Aug 13, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.16M) | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | ($1.32M) | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | ($54.5K) | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | $535.0K | Jul 13, 2023 |
| FY2021 | Mar 31, 2021 | ($16.2K) | Aug 18, 2021 |
| FY2020 | Mar 31, 2020 | $130.7K | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | ($84.2K) | Aug 13, 2020 |
| FY2019 | Mar 31, 2018 | ($3.4K) | Jul 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $224.7K | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | $322.0K | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | $241.5K | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | $454.7K | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | $816.3K | Jun 29, 2022 |
| FY2021 | May 31, 2020 | $420.0K | Aug 18, 2021 |
| FY2020 | Mar 31, 2020 | $420.0K | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | $30.5K | Aug 13, 2020 |
| FY2019 | Mar 31, 2018 | $2.6K | Jul 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.79M | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | $1.79M | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | $874.7K | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | $860.2K | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | $1.14M | Jun 29, 2022 |
| FY2019 | Mar 31, 2019 | $80.1K | Jul 15, 2019 |
| FY2019 | Mar 31, 2018 | $5.1K | Jul 15, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.56M) | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | ($1.47M) | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | ($633.3K) | Feb 19, 2025 |
| FY2024 | Mar 31, 2022 | ($405.6K) | Feb 19, 2025 |
| FY2022 | Mar 31, 2021 | ($327.4K) | Jul 13, 2023 |
| FY2021 | May 31, 2020 | ($37.7K) | Aug 18, 2021 |
| FY2021 | Mar 31, 2020 | ($37.7K) | Aug 18, 2021 |
| FY2021 | Mar 31, 2019 | ($49.6K) | Aug 18, 2021 |
| FY2020 | Mar 31, 2018 | $3.3K | Aug 13, 2020 |
| FY2019 | Nov 6, 2017 | $0 | Jul 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($4.12M) | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | ($2.98M) | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | ($847.9K) | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | $495.9K | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | $369.3K | Jun 29, 2022 |
| FY2021 | May 31, 2020 | ($67.0K) | Aug 18, 2021 |
| FY2020 | Mar 31, 2020 | ($67.0K) | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | ($79.0K) | Aug 13, 2020 |
| FY2019 | Mar 31, 2018 | ($739) | Jul 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $81.1K | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | $281 | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | $107.5K | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | $33.3K | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | $60.4K | Jun 29, 2022 |
| FY2021 | May 31, 2020 | $27.3K | Aug 18, 2021 |
| FY2021 | Mar 31, 2020 | $27.3K | Jul 13, 2021 |
| FY2020 | Mar 31, 2019 | $102 | Aug 13, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | 0 | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jun 29, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 137.36M | Jul 8, 2025 |
| FY2025 | Mar 31, 2024 | 117.17M | Jul 8, 2025 |
| FY2024 | Mar 31, 2023 | 38.50M | Feb 19, 2025 |
| FY2022 | Mar 31, 2022 | 26.32M | Jul 13, 2023 |
| FY2022 | Mar 31, 2021 | 26.28M | Jun 29, 2022 |
| FY2022 | Mar 31, 2020 | 1.06M | Jun 29, 2022 |
| FY2020 | Mar 31, 2019 | 5.01M | Aug 13, 2020 |
| FY2019 | Mar 31, 2018 | 4.00M | Jul 15, 2019 |